Yoko Endo-Takahashi

Dr. Yoko Endo-Takahashi

Tokyo University of Pharmacy and Life Sciences
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008 in Journal of Controlled Release
Verified
Journal Article
Closed access
YNYoichi Negishi
Yoichi Negishi
YEYoko Endo-Takahashi
Yoko Endo-Takahashi
TFTetsuya Fukuyama
Tetsuya Fukuyama
RSRyo Suzuki
Ryo Suzuki
TTTomoko Takizawa
Tomoko Takizawa
YAYukihiko Aramaki
Yukihiko Aramaki

24 January 2014 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YEYoko Endo-Takahashi
Yoko Endo-Takahashi
YNYoichi Negishi
Yoichi Negishi
ANArisa Nakamura
Arisa Nakamura
SUSaori Ukai
Saori Ukai
KOKotomi Ooaku
Kotomi Ooaku
YAYukihiko Aramaki
Yukihiko Aramaki
Currently, micro RNA (miRNA) is considered an attractive target for therapeutic intervention. A significant obstacle to the miRNA-based treatments is the efficient delivery of miRNA to the target tissue. We have developed polyethylene glycol-modified liposomes (Bubble liposomes (BLs)) that entrap ultrasound (US) contrast gas and can serve as both plasmid DNA (pDNA) or small interfering RNA (siRNA) carriers and US contrast agents. In this study, we investigated the usability of miRNA-loaded BLs (mi-BLs) using a hindlimb ischemia model and miR-126. It has been reported that miR-126 promotes angiogenesis via the inhibition of negative regulators of VEGF signaling. We demonstrated that mi-BLs could be detected using diagnostic US and that mi-BLs with therapeutic US could deliver miR-126 to an ischemic hindlimb, leading to the induction of angiogenic factors and the improvement of blood flow. These results suggest that combining mi-BLs with US may be useful for US imaging and miRNA delivery.

14 October 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
YEYoko Endo-Takahashi
Yoko Endo-Takahashi
YNYoichi Negishi
Yoichi Negishi
The regulation of gene expression is a promising therapeutic approach for many intractable diseases. However, its use in clinical applications requires the efficient delivery of nucleic acids to target tissues, which is a major challenge. Recently, various delivery systems employing physical energy, such as ultrasound, magnetic force, electric force, and light, have been developed. Ultrasound-mediated delivery has particularly attracted interest due to its safety and low costs. Its delivery effects are also enhanced when combined with microbubbles or nanobubbles that entrap an ultrasound contrast gas. Furthermore, ultrasound-mediated nucleic acid delivery could be performed only in ultrasound exposed areas. In this review, we summarize the ultrasound-mediated nucleic acid systemic delivery system, using microbubbles or nanobubbles, and discuss its possibilities as a therapeutic tool.

29 August 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AMAya Matsui
Aya Matsui
HYHideaki Yokoo
Hideaki Yokoo
YNYoichi Negishi
Yoichi Negishi
YEYoko Endo-Takahashi
Yoko Endo-Takahashi
NCNicole A. L. Chun
Nicole A. L. Chun
TMTakashi Murakami
Takashi Murakami
Chemokines are involved in multiple aspects of pathogenesis and cellular trafficking in tumorigenesis. In this study, we report that the latest member of the C-X-C-type chemokines, CXCL17 (DMC/VCC-1), recruits immature myeloid-derived cells and enhances early tumor progression. CXCL17 was preferentially expressed in some aggressive types of gastrointestinal, breast, and lung cancer cells. CXCL17 expression did not impart NIH3T3 cells with oncogenic potential in vitro, but CXCL17-expressing NIH3T3 cells could form vasculature-rich tumors in immunodeficient mice. Our data showed that CXCL17-expressing tumor cells increased immature CD11b+Gr1+ myeloid-derived cells at tumor sites in mice and promoted CD31+ tumor angiogenesis. Extensive chemotactic assays proved that CXCL17-responding cells were CD11b+Gr1highF4/80− cells (∼90%) with a neutrophil-like morphology in vitro. Although CXCL17 expression could not increase the number of CD11b+Gr1+ cells in tumor-burdened SCID mice or promote metastases of low metastatic colon cancer cells, the existence of CXCL17-responding myeloid-derived cells caused a striking enhancement of xenograft tumor formation. These results suggest that aberrant expression of CXCL17 in tumor cells recruits immature myeloid-derived cells and promotes tumor progression through angiogenesis.

7 January 2010 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
YNYoichi Negishi
Yoichi Negishi
DODaiki Omata
Daiki Omata
HIHiroshi Iijima
Hiroshi Iijima
YTYasuko Takabayashi
Yasuko Takabayashi
KSKentaro Suzuki
Kentaro Suzuki
YAYukihiko Aramaki
Yukihiko Aramaki

1 January 2013 in Biomaterials
Verified
Journal Article
Closed access
YNYoichi Negishi
Yoichi Negishi
NHNobuhito Hamano
Nobuhito Hamano
YTYuka Tsunoda
Yuka Tsunoda
YOYusuke Oda
Yusuke Oda
BCBatsuren Choijamts
Batsuren Choijamts
YAYukihiko Aramaki
Yukihiko Aramaki